compound, pharmaceutical composition, method for inhibiting double leucine zipper kinase, method for treating a double leucine zipper kinase mediated disease and method for obtaining an effect on a patient

摘要

Disclosed herein are compounds which inhibit the activity of double leucine zipper kinase (dlk) kinase (map3k12), pharmaceutical compositions and methods for treating dlk-mediated diseases, such as neurological disorders resulting from traumatic injury to the neurons of the central nervous system and peripheral nervous system (eg, stroke, traumatic brain injury, spinal cord injury), or resulting from a chronic neurodegenerative disorder (eg alzheimer's disease, frontotemporal dementia, parkinson's disease, huntington's disease, amyotrophic lateral sclerosis, spinocerebellar degeneration, progressive supranuclear palsy, lewy body disease, kennedy disease and other related conditions), neuropathies resulting from neurological damage (chemotherapy-induced peripheral neuropathy, diabetic neuropathy and related disorders) and cognitive disorders caused by pharmacological intervention (eg, chemotherapy-induced cognitive impairment, also known as chemotherapy fog).